About the API
Ixazomib citrate is used for treating multiple myeloma in its finished dose formulation. Its mechanism of action involves functioning as a proteasome inhibitor, disrupting the normal function of proteasomes in cells.
At Teva api we offer Ixazomib Citrate API Form II, which is the same as the brand. In addition, our own proprietary process leverages our expertise to handle boronates, resulting in a high-quality API. GMP material is now available, and full validation will be completed in March 2024.
Ixazomib Citrate API is currently developed and produced for R&D purposes and regulatory submissions only.
About the API
Systematic name
2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid
Trade name(s)
Ninlaro
Technology
Synthetic
Molecular Formula
C20H23BCl2N2O9
Molecular Weight
517.1 g/mol
Therapeutic category
Oncology
Available formulations
Oral Solid